Dicerna Pharmaceuticals

Dicerna

Scientific Publications

Our GalXC™ and GalXC-Plus™ Technologies Scientific Publications

Below please find several of the scientific publications and presentations developed by members of the Dicerna clinical development team.

The findings published below play an integral role in the creation, development and optimization of our GalXC™ RNAi technology platform. Dicerna’s scientists are working to discover and develop next-generation therapies that aim to restore health by silencing the genes that cause or contribute to disease. 

Oligonucleotides: Chemistry & Therapeutics Symposium: Comparison of clinical oligonucleotides against HBV – what are crucial PK/PD features?, Apr. 2021.

Oligonucleotide and Precision Therapeutics Congress: Cell Type-Targeted Therapeutic Oligonucleotide Delivery in the CNS, Mar. 2021.

Kidney International Reports: Hepatic lactate dehydrogenase A is an RNA interference target for the treatment of all known types of primary hyperoxaluria, Feb. 2021.

AASLD The Liver Meeting® Digital Experience™ 2020: HBV RNAi inhibitor RG6346 in Phase 1b-2a trial was safe, well-tolerated and resulted in substantial and durable reductions in serum HBsAg levels, Nov. 2020.

TIDES Europe: Progress on a Pipeline of Extrahepatic RNAi Therapeutics, Nov. 2020.

American Society of Nephrology (ASN) Kidney Week 2020: Clinical and Economic Impact of Primary Hyperoxaluria: A Retrospective Claims Analysis, Oct. 2020.

American Society of Nephrology (ASN) Kidney Week 2020: PHYOX3: A Long-Term, Open-Label Extension Trial of Nedosiran in Patients with Primary Hyperoxaluria Type 1, 2 or 3, Oct. 2020.

Virtual Alpha-1 National Conference: Emerging Therapies in Alpha-1 DCR-A1AT as a Potential Therapeutic for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease, June 2020.

Nanoscale: The role of surface chemistry in serum protein corona-mediated cellular delivery and gene silencing with lipid nanoparticles, May 2019.

OHF International Workshop: PHYOX™: A Safety and Tolerability Study of DCR-PHXC In Primary Hyperoxaluria Types 1 and 2, June 2019.

Molecular Therapy: RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade, Nov. 2018.

Molecular Therapy: Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria, Aug. 2018.

AASLD: Preclinical Characterization of GalXC™ RNAi Therapeutics Targeting Different Regions of the HBV Genome, Nov. 2018.

ASN: A Safety and Tolerability Study of DCR-PHXC in Primary Hyperoxaluria Types 1 and 2, Oct. 2018.

Molecular Cancer Therapeutics: β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models, Aug. 2018.

Molecular Therapy: Inhibition of Glycogen Synthase II with RNAi Prevents Liver Injury in Mouse Models of Glycogen Storage Diseases, July 2018.

Hepatology: Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice, May 2018.

Molecular Cancer Therapeutics: Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin, Mar. 2017.

Molecular Therapy: Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1, Jan. 2016.

Molecular Therapy: Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo, Oct. 2013.

Our mission

We interfere with disease

We use RNA interference, or RNAi, to create medicines that silence the genes that cause or contribute to disease. Our goal is to provide life-changing therapies to people living with rare and common diseases.

novo nordisk

Effective 28 December 2021 Dicerna Pharmaceuticals, Inc. is a wholly owned subsidiary of Novo Nordisk A/S

PRESS RELEASE
CONTINUE TO DICERNA.COM
VISIT NOVONORDISK.COM